Blood

PI-103, a Dual Inhibitor of Class I Phosphatidylinositide 3-Kinase and mTOR, Has Anti-Leukemic Activity in Acute Myeloid Leukemia.

Blood

Sophie Park, Nicolas Chapuis, Valerie Bardet, Lise Willems, Jerome Tamburini, Zachary A. Knight, Kevan M. Shokat, Nabih Azar, Norbert Ifrah, Francois Dreyfus, Patrick Mayeux, Catherine Lacombe, Didier Bouscary

Importance of PI3 Kinase Family for Crosstalk between Chronic Lymphocytic Leukemia B Cells and the Stromal Microenvironment: Therapeutic Implications.

Blood

Matthias T.W. Niedermeier, Justyna Rawluk, Zachary Knight, Kevan Shokat, William G. Wierda, Michael J. Keating, Jan A. Burger

Knock-outs and inhibitors: one and the same?.

Blood

Zachary A. Knight, Kevan M. Shokat

Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2.

Blood

Moll M, Snyder-Cappione J, Spotts G, Hecht FM, Sandberg JK, Nixon DF

Expansion of CD7(low) and CD7(negative) CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment.

Blood

Aandahl EM, Quigley MF, Moretto WJ, Moll M, Gonzalez VD, Sönnerborg A, Lindbäck S, Hecht FM, Deeks SG, Rosenberg MG, Nixon DF, Sandberg JK

Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.

Blood

Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narváez AB, Hunt P, Martin JN, Kahn JO, Levy J, McGrath MS, Hecht FM

Protection against thrombosis in mice lacking PAR3.

Blood

Weiss EJ, Hamilton JR, Lease KE, Coughlin SR

Pages